Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 5/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridine SCHEMBL4792433 | 0.85 | PNMT (0.66) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL6304990 | 0.85 | PNMT (0.53) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL3247336 | 0.81 | PNMT (0.61) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL2401358 | 0.79 | CYP3A4 (0.55) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL222040 | 0.79 | HTR2C (0.49) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL30751773 | 0.79 | CYP3A4 (0.55) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL6312101 | 0.73 | HTR2C (0.47) | ALDH1A1GLAMAPTHPGDACHE | |
| Acridine SCHEMBL27523545 | 0.73 | ALDH1A1 (0.71) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL11833898 | 0.73 | CYP3A4 (0.46) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL6307312 | 0.71 | HTR2C (0.64) | PNMTCD44MAOBHTR3AASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | ALDH1A1 2434/4885GLA 3149/4885MAPT 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.